Subject:
- Active Substance: Mepolizumab
- Name: Nucala®
- Therapeutic area: Hypereosinophilic syndrome
- Pharmaceutical company: GlaxoSmithKline GmbH & Co. KG
Time table:
- Start: 01.12.2021
- Final decision by G-BA: 19.05.2022
Final decision:
- Hint for a considerable additional benefit